Medicare fraud enforcement has become a larger focus in 2026 as the Trump administration expands federal anti-fraud efforts across health programs and medical suppliers. On July 8, 2026, administration officials used new Medicare billing data and enforcement figures to spotlight a surge in claims tied to skin substitute products, also known in federal materials as allografts.
CMS says claims surged as federal officials denied most recent submissions
The Centers for Medicare & Medicaid Services said Medicare claims for skin substitute products rose from about $200 million in 2019 to $14.4 billion in 2025, a 7,100% increase cited by administration officials during a press event in Milwaukee, Wisconsin, and in comments provided to Fox News. CMS Administrator Mehmet Oz said the agency identified 4,200 suspicious claims totaling $224 million through May 2026, and officials said 96% of claims submitted since March were denied.
Those products are used in wound care and related treatment, but CMS and federal investigators have said the category has also become a fraud risk because of unusually fast billing growth and questions about whether some products were medically necessary or delivered as billed. In a 2025 proposed Medicare physician payment rule, CMS separately reported that Part B spending on skin substitutes rose from $252 million in 2019 to more than $10 billion in 2024, showing a similar sharp increase in federal spending.
The administration’s announcement focused on claim denials before payment, not a final court finding in each case. Federal officials have not publicly released a provider-by-provider list tied to the 4,200 suspicious skin substitute claims described this week, and the administration has not said in its public summary how many individual patients or medical practices were directly affected by those denials.
The latest figures were announced in Milwaukee on Wednesday, July 8, putting Wisconsin at the center of the public rollout even though the billing and enforcement actions described by CMS were national in scope. Oz said during the Milwaukee appearance that the level of suspect billing was large enough to strain hospitals, physician groups and the broader health care system, according to the Fox report that first detailed the new numbers.
What remains unclear is how much of the skin substitute billing flagged by CMS was connected to Wisconsin providers specifically. Neither CMS nor the White House task force has released a comprehensive state-by-state breakdown of the 4,200 suspicious claims or the $224 million in charges identified through May, so it is not yet possible to confirm Wisconsin’s share from the public information released so far.
Officials did provide more detailed national figures on durable medical equipment, another major enforcement target. CMS said payments were suspended to 102 suppliers and billing privileges were revoked for 725 more, while a spokesperson for Vice President JD Vance’s office said the suppliers under suspension represented 8.6% of all Medicare-funded durable medical equipment in 2025. That category includes items such as wheelchairs, walkers and hospital beds.
The enforcement campaign is part of the White House Task Force to Eliminate Fraud, created by President Donald Trump in Executive Order 14395 on March 16, 2026, with Vance designated as chair. White House and Justice Department materials say the task force coordinates agencies across government to identify fraud, waste and abuse in federal benefit programs, including health care reimbursements.
Federal officials have tied the skin substitute crackdown to broader concerns about billing patterns, inflated prices and medically unnecessary services. HHS OIG and the Justice Department said in the 2026 National Health Care Fraud Takedown that schemes involving durable medical equipment, skin substitutes and wound care products were part of more than $4 billion in alleged fraudulent claims. In a separate California case filed in May, federal prosecutors said a wound care clinic billed far above the national average and, in at least one instance, sought payment for skin graft services a beneficiary did not receive.
For Medicare patients and providers, the practical effect is increased prepayment scrutiny and a higher likelihood that unusual claims will be stopped before funds go out. CMS has said it is continuing nationwide moratoria and other screening measures in high-risk categories, while the administration says additional anti-fraud enforcement will continue through the task force’s interagency review process.